Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Integrated Biomarker Analysis for Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Combined PD1/PDL1 Inhibitor Treatment in Patients of Advanced Gastric Cancer With Peritoneal Metastasis

NCT05661110 is registered in ClinicalTrials.gov with Affiliated Cancer Hospital & Institute of Guangzhou Medical University as lead sponsor.

NCT NCT05661110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05661110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Integrated Biomarker Analysis for Hyperthermic Intraperitoneal Chemotherapy(HIPEC) Combined PD1/PDL1 Inhibitor Treatment in Patients of Advanced Gastric Cancer With Peritoneal Metastasis
Lead sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2023
Completion date
December 31, 2027
Enrollment
46 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer